INVIMA will prioritize procedures of pharmaceutical products identified and classified as first and second line for the treatment of symptoms and complications of COVID-19 in critical and non-critical patients by the Ministry of Health and Social Protection

INVIMA and the Ministry of Health and Social Protection will prioritize the procedures related with pharmaceutical products identified as essential in first and second line that can be used in the treatment of symptoms and complications of COVID-19, taking into account the recommendations of the World Health Organization, since there is no certainty about the efficacy of the different medications.

First-line drugs are those used in the treatment of non-critical patients and management of COVID-19 symptoms, for example, cough, headache, fever, diarrhea, and second-line drugs are essential for treating critically ill patients, such as, those hospitalized and/or in the Intensive Care Unit.

INVIMA will prioritize the procedures that are pending study and decision associated with the following therapeutic groups that use specific active ingredients:

  • Dopaminergic and adrenergic agents
  • B2 Selective Agonists
  • B2 Selective Agonists + Anticholinergics
  • B2 Selective Agonists + Corticosteroids
  • Amino Acids and its combinations
  • Analgesics / Antipyretics
  • Opioid pain reliever
  • General anesthetics
  • Hypnotic anesthetic
  • H2 receptor histamine antagonists
  • Anticholinergics
  • Antiemetics
  • Antibiotics
  • Antimalarials
  • Antiseptics / Antiseptics
  • Antithrombotics
  • Antivirals
  • Neuromuscular blockers / relaxers
  • Corticosteroids
  • Medicinal gases
  • Proton pump inhibitor
  • Mucolytics
  • Neuroleptics
  • Electrolytes and its combinations
  • Sedatives
  • Vaccines
  • Vasopressor

More details can be found by following this link:

See document

For more information contact our team